Skip to main content

DexCom, Inc.

corporate_fare Company Profile

DexCom, Inc.

DXCM·NASDAQ·Industrial Applications And Services·CIK 0001093557

Dexcom, Inc. is a medical device company that designs, develops, and sells continuous glucose monitoring (CGM) systems for managing diabetes and metabolic health. These systems are used by patients, caregivers, and clinicians globally. The company commercialized its first product in 2006 after receiving FDA approval. Dexcom launched its latest generation system, the Dexcom G7 Continuous Glucose Monitoring System (G7), in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System (G7 15 Day) in late 2025. In August 2024, Dexcom introduced Stelo, a biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin, marking the first over-the-counter glucose biosensor in the U.S. The G7 system received Conformité Européenne Marking (CE Mark) approval in March 2022 and marketing authorization from the FDA in December 2022 through the 510(k) review process. The G7 is classified as a Class II integrated continuous glucose monitoring system (iCGM) by the FDA, subject to special controls for accuracy, reliability, and clinical relevance. Its technical performance, including the glucose value algorithm, communication with display and mobile devices, and compatibility with Dexcom Clarity (cloud-based reporting software), is substantially equivalent to the prior generation Dexcom G6 Continuous Glucose Monitoring Integrated System (G6). The G7 is cleared in the United States for all people with diabetes aged two years and older.

DexCom, Inc. (NASDAQ:DXCM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for DXCM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for DXCM spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • DexCom 10-Q: Q3 Revenue $1.34B, Operating Income Up 35%, $1.0B Buyback Completed
  • Dexcom Beats on Q3, Raises 2026 Guidance and Authorizes $1.0 Billion Buyback
  • DexCom Posts $275.1M Third-Quarter Net Income
  • NEJM Publication of CONNECT Trial Boosts DexCom's Medicare Coverage Hopes
  • Dexcom Q2 Revenue Jumps 13% to $1.31B, Operating Income Surges 50%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.66B
Net Income
$836.3M
Diluted EPS
$2.09
Op. Cash Flow
$1.44B
Free Cash Flow
$1.08B
Gross Profit
$2.8B
Operating Income
$911.8M
Cash & Equivalents
$917.7M
Debt / Equity
0.00×
Net Margin
17.9%
Shares Outstanding
384.8M sh
Source: 10-K · filed 2026-02-12 · accession 0001093557-26-000027

Short Interest & Short Volume

2.81 days to cover

FINRA reported short interest of 15,933,006 shares in DXCM as of the October 30, 2026 settlement, a 1.6% increase from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 58.3% of DXCM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)15,933,006 shares as of October 30, 2026
Change vs prior period▲ 1.6%
Days to cover2.81 at avg daily volume of 5,675,513
Daily short volume (FINRA facilities)58.3% of 1,338,494 shares on November 20, 2026
5-day average short volume57.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with D →
$78.18 -1.44% today
52-week range · as of 2026-10-29 $54.11 – $92.59
Market cap
$29.58B
Volume
4.6M (1.0× avg)
3-mo avg 4.7M
Live data · 2026-11-21 06:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DXCM - Latest Insights

DXCM
Oct 29, 2026, 5:22 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $81.30
Real-time Price: $78.18 info
Change: -$3.12 (-4%) info
Market Cap: $29.582B info
DXCM
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.20
Real-time Price: $78.18 info
Change: -$1.02 (-1%) info
Market Cap: $29.582B info
DXCM
Oct 29, 2026, 4:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $79.93
Real-time Price: $78.18 info
Change: -$1.75 (-2%) info
Market Cap: $29.582B info
DXCM
Oct 15, 2026, 10:04 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $87.85
Real-time Price: $78.18 info
Change: -$9.67 (-11%) info
Market Cap: $29.582B info
DXCM
Jul 30, 2026, 5:21 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $80.39
Real-time Price: $78.18 info
Change: -$2.21 (-3%) info
Market Cap: $29.582B info
DXCM
Jul 30, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $79.00
Real-time Price: $78.18 info
Change: -$0.8238 (-1%) info
Market Cap: $29.582B info
DXCM
Jul 30, 2026, 4:02 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $75.98
Real-time Price: $78.18 info
Change: +$2.20 (+3%) info
Market Cap: $29.582B info
DXCM
Jun 12, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $75.54
Real-time Price: $78.18 info
Change: +$2.63 (+3%) info
Market Cap: $29.582B info
DXCM
Jun 06, 2026, 2:45 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $71.50
Real-time Price: $78.18 info
Change: +$6.68 (+9%) info
Market Cap: $29.582B info
DXCM
May 28, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $72.19
Real-time Price: $78.18 info
Change: +$5.98 (+8%) info
Market Cap: $29.582B info
DXCM
May 26, 2026, 9:46 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $71.15
Real-time Price: $78.18 info
Change: +$7.03 (+10%) info
Market Cap: $29.582B info
DXCM
May 15, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $59.66
Real-time Price: $78.18 info
Change: +$18.52 (+31%) info
Market Cap: $29.582B info
DXCM
May 14, 2026, 4:25 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $60.51
Real-time Price: $78.18 info
Change: +$17.66 (+29%) info
Market Cap: $29.582B info
DXCM
Apr 30, 2026, 5:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $56.69
Real-time Price: $78.18 info
Change: +$21.49 (+38%) info
Market Cap: $29.582B info
DXCM
Apr 30, 2026, 4:02 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $60.52
Real-time Price: $78.18 info
Change: +$17.66 (+29%) info
Market Cap: $29.582B info
DXCM
Apr 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $64.09
Real-time Price: $78.18 info
Change: +$14.09 (+22%) info
Market Cap: $29.582B info
DXCM
Mar 02, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $73.78
Real-time Price: $78.18 info
Change: +$4.40 (+6%) info
Market Cap: $29.582B info
DXCM
Feb 26, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $74.38
Real-time Price: $78.18 info
Change: +$3.80 (+5%) info
Market Cap: $29.582B info
DXCM
Feb 12, 2026, 5:20 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $66.00
Real-time Price: $78.18 info
Change: +$12.18 (+18%) info
Market Cap: $29.582B info
DXCM
Feb 12, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $65.54
Real-time Price: $78.18 info
Change: +$12.64 (+19%) info
Market Cap: $29.582B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets